iShares Gold Trust vs Organon & Co. Common Stock — how do they compare? iShares Gold Trust trades at $77.8 (market cap $62.13B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: iShares Gold Trust is far larger — about 17.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 51 Days and Organon & Co. Common Stock for 0 Days on average.
| IAU | OGN | |
|---|---|---|
Market Cap | $62.13B | $3.62B |
Volume | 3,713,095 | 2,892,999 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $13.81 |
52-Week Low | $74.21 | $5.70 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Signals from Pluang's Aura AI — not financial advice
IAU shares are trading at $78.25, down 0.11% with bearish technical signals dominating the short-term outlook. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent soft inflation data has provided some support. Technical indicators show selling pressure outweighing buying signals, with moving averages pointing downward and key resistance at $79.
The stock faces headwinds from monetary policy uncertainty and yield pressures, but potential exists if inflation concerns resurface. Key risks include continued rate hike expectations and dollar strength, while opportunities may emerge from safe-haven demand during market volatility. The technical setup suggests caution in the near term with support at $78.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →